When the clock is ticking for a patient who has exhausted every approved therapeutic intervention, the distinction between a “clinical trial” and “clinical survival” becomes life-defining. For the critically ill, the dual pillars of Expanded Access (EA) and Right to Try (RTT) represent more than just regulatory pathways; they are the final conduits of hope in a race against terminal progression. Managing these options requires a delicate mastery of the tension between the FDA’s rigorous oversight in EA and the statutory autonomy granted by RTT. Without these mechanisms, the most vulnerable patients are left stranded between a protocol they don’t qualify for and a therapy they cannot legally touch. For regulatory affairs experts, the newly finalized 2026 guidance is the definitive playbook for navigating this high-stakes landscape where speed, safety, and ethics collide.
The new FDA guidance on expanded access (EA) to investigational drugs focuses heavily on streamlining the administrative burden of the Investigational New Drug (IND) process with that for the EA program. The guidance highlights the key requirements for the EA program such as transparency of the EA program by maintaining a public-facing policy that describes clear criteria for request evaluation and specific contact points, technical framework for reporting AEs in EA populations without jeopardizing the core clinical development program and clarification for the FDA approval process for expanded access programs.
The expanded access program is often compared to the Right To Try (RTT) program. While both pathways serve the same desperate patient population, the 2026 guidance draws sharp lines between the EA and RTT routes
| Feature | Expanded Access (21 CFR 312) | Right to Try (RTT Act) |
| Regulatory Gatekeeper | Requires explicit FDA authorization and IND clearance. | Bypasses the FDA; agreement is strictly between sponsor and physician. |
| Safety Oversight | Mandatory FDA review of dosing and safety protocols. | Responsibility for safety monitoring rests entirely with the sponsor. |
| Evidence Threshold | Requires a “probable risk-benefit” assessment by the Agency. | Limited to drugs that have successfully cleared a Phase 1 trial. |
| Liability Protections | Limited; governed by traditional IND regulations. | Provides broad federal liability protections for sponsors and doctors. |
The guidance clarifies that RTT does not supersede EA; rather, it provides a “bypass” for sponsors willing to accept the liability and oversight risks in exchange for speed. Conversely, EA remains the “gold standard” for sponsors who prefer the regulatory “safety net” provided by the FDA’s expert review.
For the regulatory professional, the guidance clarifies that RTT does not replace EA; rather, they are distinct pathways. The FDA notes that a sponsor’s decision to provide a drug under RTT does not preclude them from also offering it via EA. However, the documentation requirements for EA remain more robust, particularly regarding the “Treatment Protocol” and the necessity of demonstrating that the EA use will not interfere with the initiation or completion of clinical investigations.
The FDA’s finalized guidance provides the much-needed procedural “scaffolding” to support expanded access programs in an increasingly complex legal environment. By delineating the technical requirements for INDs and the role of IRBs, the Agency reaffirms its commitment to balancing patient hope with rigorous safety monitoring. Regulatory affairs teams must now integrate these clarifications into their Standard Operating Procedures (SOPs) to ensure seamless transitions between development and compassionate use. Ultimately, a thorough grasp of this guidance is the differentiator in successfully navigating the ethical and legal hurdles of pre-market access. As the industry moves forward, this document will remain the definitive guide for bringing investigational hope to the bedside safely and compliantly.
